Nasdaq:US$15.16 (+0.00) | HKEX:HK$23.20 (-0.30) | AIM:£2.24 (-0.01)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)